| First Author | Serizawa K | Year | 2023 |
| Journal | J Neuroimmunol | Volume | 380 |
| Pages | 578109 | PubMed ID | 37210799 |
| Mgi Jnum | J:343150 | Mgi Id | MGI:7564177 |
| Doi | 10.1016/j.jneuroim.2023.578109 | Citation | Serizawa K, et al. (2023) Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice. J Neuroimmunol 380:578109 |
| abstractText | We challenged to create a mouse model of neuromyelitis optica spectrum disorder (NMOSD) induced by AQP4 peptide immunization. Intradermal immunization with AQP4 p201-220 peptide induced paralysis in C57BL/6J mice, but not in AQP4 KO mice. AQP4 peptide-immunized mice showed pathological features similar to NMOSD. Administration of anti-IL-6 receptor antibody (MR16-1) inhibited the induction of clinical signs and prevented the loss of GFAP/AQP4 and deposition of complement factors in AQP4 peptide-immunized mice. This novel experimental model may contribute to further understanding the pathogenesis of NMOSD, elucidating the mechanism of action of therapeutic agents, and developing new therapeutic approaches. |
